EP2709646A4 - VANCOMYCIN DRY POWDER COMPOSITIONS AND ASSOCIATED METHODS - Google Patents

VANCOMYCIN DRY POWDER COMPOSITIONS AND ASSOCIATED METHODS

Info

Publication number
EP2709646A4
EP2709646A4 EP12785744.9A EP12785744A EP2709646A4 EP 2709646 A4 EP2709646 A4 EP 2709646A4 EP 12785744 A EP12785744 A EP 12785744A EP 2709646 A4 EP2709646 A4 EP 2709646A4
Authority
EP
European Patent Office
Prior art keywords
dry powder
associated methods
powder compositions
vancomycin
vancomycin dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12785744.9A
Other languages
German (de)
French (fr)
Other versions
EP2709646A1 (en
Inventor
John Lord
Jaakko Taneli Jouhikainen
Herman E Snyder
Pravin Soni
Mei-Chang Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savara Inc
Original Assignee
Savara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savara Inc filed Critical Savara Inc
Publication of EP2709646A1 publication Critical patent/EP2709646A1/en
Publication of EP2709646A4 publication Critical patent/EP2709646A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP12785744.9A 2011-05-19 2012-05-21 VANCOMYCIN DRY POWDER COMPOSITIONS AND ASSOCIATED METHODS Withdrawn EP2709646A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487971P 2011-05-19 2011-05-19
PCT/US2012/038775 WO2012159103A1 (en) 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods

Publications (2)

Publication Number Publication Date
EP2709646A1 EP2709646A1 (en) 2014-03-26
EP2709646A4 true EP2709646A4 (en) 2015-05-13

Family

ID=47177374

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12785744.9A Withdrawn EP2709646A4 (en) 2011-05-19 2012-05-21 VANCOMYCIN DRY POWDER COMPOSITIONS AND ASSOCIATED METHODS

Country Status (11)

Country Link
EP (1) EP2709646A4 (en)
JP (1) JP6012716B2 (en)
KR (1) KR101763195B1 (en)
CN (1) CN103717231B (en)
AU (1) AU2012254999B2 (en)
BR (1) BR112013029803B1 (en)
CA (2) CA2981038C (en)
IL (1) IL229506B (en)
MX (1) MX346244B (en)
SG (1) SG195038A1 (en)
WO (1) WO2012159103A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798263T3 (en) 2005-12-08 2020-12-10 Insmed Inc Lipid-based compositions of anti-infectives for treating lung infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
MX2015006681A (en) 2012-11-29 2016-04-06 Insmed Inc Stabilized vancomycin formulations.
CN109568319A (en) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 Non-selective kinase inhibitor
CN104043104B (en) * 2013-03-15 2018-07-10 浙江创新生物有限公司 The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin
JP6483714B2 (en) 2013-10-11 2019-03-13 ローレンス エス． ジスマン， Spray-dried formulation
EP3110426A1 (en) * 2014-02-28 2017-01-04 Algipharma As Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
ES2903419T3 (en) 2014-03-14 2022-04-01 Azurity Pharmaceuticals Inc Composition and method for vancomycin oral liquid
ES2755941T3 (en) 2014-05-15 2020-04-24 Insmed Inc Methods of treating nontuberculous mycobacterial lung infections
RS61418B1 (en) * 2014-11-06 2021-03-31 Xellia Pharmaceuticals Aps Glycopeptide compositions
CA2974220C (en) 2015-02-06 2023-05-16 Latitude Pharmaceuticals, Inc. Aqueous solution formulations of vancomycin
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
JP2020500183A (en) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド Combination therapy for the treatment of pulmonary hypertension
CN106963939A (en) * 2017-03-22 2017-07-21 永信药品工业（昆山）股份有限公司 Vancomycin hydrochloride pharmaceutical composition and preparation method thereof
JP7210476B2 (en) * 2017-05-22 2023-01-23 インスメッド インコーポレイテッド Lipo-glycopeptide cleavable derivatives and uses thereof
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3866829A1 (en) * 2018-10-15 2021-08-25 Savara Inc. Separation of vancomycin and its degradation products

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041833A1 (en) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
WO2001032144A1 (en) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
WO2003037303A1 (en) * 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
IT1203660B (en) 1982-10-08 1989-02-15 Glaxo Group Ltd DEVICES TO ADMINISTER DRUGS TO PATIENTS AND PACK OF BLISTERS FOR THEM
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
JPH03193735A (en) * 1989-12-22 1991-08-23 Shionogi & Co Ltd Stabilized composition of glycopeptide-based antibiotic
JPH05963A (en) 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JP4142149B2 (en) * 1997-07-10 2008-08-27 明治製菓株式会社 Vancomycin lyophilized formulation
DE10358387A1 (en) * 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder containing low molecular weight dextran and process for their preparation
FR2872044B1 (en) * 2004-06-28 2007-06-29 Flamel Technologies Sa PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
CA2739897C (en) * 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
JP2012522009A (en) 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
RU2577698C2 (en) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Dry powder formulations and methods of treating pulmonary diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041833A1 (en) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
WO2001032144A1 (en) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
WO2003037303A1 (en) * 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Handbook of Pharmaceutical Excipients. Fifth Edition", 2006, PHARMACEUTICAL PRESS, article "Leucine", pages: 412, XP002729817 *
M. J. DE JESUS VALLE ET AL: "Pulmonary versus Systemic Delivery of Antibiotics: Comparison of Vancomycin Dispositions in the Isolated Rat Lung", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 51, no. 10, 6 August 2007 (2007-08-06), pages 3771 - 3774, XP055140353, ISSN: 0066-4804, DOI: 10.1128/AAC.00099-07 *
PRAJAKTA S. GADGILP: "A comparative study between high potency dry powder inhalation and nebulized solution of vancomycin hydrochloride for lung delivery", 11 August 2011 (2011-08-11), pages FP - 109, XP055140679, Retrieved from the Internet <URL:http://search.proquest.com/pqdtscieng/docview/889930798as02134> [retrieved on 20141111] *
REINHARD VEHRING: "Pharmaceutical Particle Engineering via Spray Drying", PHARMACEUTICAL RESEARCH, vol. 25, no. 5, 28 November 2007 (2007-11-28), KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, pages 999 - 1022, XP019613056, ISSN: 1573-904X *
See also references of WO2012159103A1 *

Also Published As

Publication number Publication date
BR112013029803A2 (en) 2017-01-17
MX2013013503A (en) 2014-05-12
AU2012254999B2 (en) 2016-02-11
CA2981038A1 (en) 2012-11-22
IL229506A0 (en) 2014-01-30
CN103717231B (en) 2016-08-17
CA2981038C (en) 2018-09-25
NZ704819A (en) 2016-05-27
CA2836643C (en) 2017-11-14
KR101763195B1 (en) 2017-07-31
CN103717231A (en) 2014-04-09
KR20140032450A (en) 2014-03-14
CA2836643A1 (en) 2012-11-22
NZ618002A (en) 2015-03-27
EP2709646A1 (en) 2014-03-26
JP2014515356A (en) 2014-06-30
BR112013029803B1 (en) 2021-07-13
SG195038A1 (en) 2013-12-30
IL229506B (en) 2019-07-31
MX346244B (en) 2017-03-13
WO2012159103A1 (en) 2012-11-22
JP6012716B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
EP2709646A4 (en) VANCOMYCIN DRY POWDER COMPOSITIONS AND ASSOCIATED METHODS
EP2734049A4 (en) METHODS AND PROBIOTIC COMPOSITIONS
EP2648788A4 (en) DRY POWDER INHALER
EP2635282A4 (en) COMPOSITIONS AND METHODS FOR TREATING MYELFIBROSIS
EP2675909A4 (en) COMPOSITION OF GLUCOSYLSTEVIA
EP2720561A4 (en) COMPOSITION OF STÉVIA
EP2925298A4 (en) STABILIZED VANCOMYCIN FORMULATIONS
EP2713762A4 (en) COMPOSITION OF STÉVIA
EP2709972A4 (en) NON-FLAMMABLE COMPOSITIONS OF CHLOROTRIFLUOROPROPENE
EP2736491A4 (en) COMPOSITIONS OF BEPOSTATIN
EP2675819A4 (en) MOLECULAR MARKING COMPOSITIONS AND METHODS
DK2696848T3 (en) FREEZE-DRIED NANOSUS SUSPENSIONS OF MEDICINAL PRODUCTS
EP2897583A4 (en) SUSPENDED POWDER-LIKE COSMETIC COMPOSITIONS AND CORRESPONDING METHODS
BR112015009718A2 (en) composition of matter and article.
EP2785823A4 (en) COMPOSITIONS AND METHODS OF CLEANING
CO6980141A1 (en) Compounds and compositions of catholic polyglyceryl
BR112014009802A2 (en) nanosilic containing bismaleimide compositions
PT2736340T (en) BIOCONTROL OF NEMÁTODOS
BR112014006291A2 (en) composition and use of composition
EP2612887A4 (en) POLYSILOXANE COMPOSITION AND CURED PRODUCT OF SAID COMPOSITION
BR112013019287A2 (en) innovative composition of pesticides
CO6940377A2 (en) Freeze-dried formulations of fgf-18
EP2723390A4 (en) SERPINA1 SERIES: COMPOSITIONS AND METHODS OF TREATMENT
EP2857482A4 (en) PERFUME COMPOSITION
EP2857421A4 (en) CELLULOSE POWDER

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194310

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101AFI20141114BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101AFI20141121BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150415

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101AFI20150409BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220628

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1194310

Country of ref document: HK